Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer

Table 3

Statistical analysis of differential lipids to distinguish early-stage NSCLC from HC group.

Peak	Lipid	Polarity	VIP; value	Fold; Change	p; value	Peak	Lipid	Polarity	VIP; value	Fold; Change	p; value	Peak	Lipid	Polarity	VIP; value	Fold; Change	p; value
1	PC(P-18:0/15:1)	POS	1.22	10.41	<0.001	21	TG(14:0/16:1/18:1)	POS	1.37	1.73	<0.001	41	TG(17:0/17:2/19:0)	POS	1.29	1.54	<0.001
2	TG(14:0/16:0/16:1)	POS	1.21	2.39	0.011	22	PE(24:4/12:0)	POS	1.88	1.72	<0.001	42	PC(18:3/22:6)	POS	1.04	1.54	<0.001
3	DG(18:1/18:1)	POS	2.05	2.28	<0.001	23	TG(16:1/18:3/18:3)	POS	1.06	1.70	<0.001	43	TG(16:0/18:0/18:0)	POS	1.48	1.53	<0.001
4	TG(14:0/16:0/18:1)	POS	1.64	2.27	<0.001	24	PC(P-20:0/19:0)	POS	1.60	1.68	<0.001	44	TG(16:0/16:1/18:3)	POS	1.28	1.53	<0.001
5	CE(18:4)	POS	1.46	2.03	<0.001	25	PC(18:3/26:2)	POS	1.37	1.67	<0.001	45	TG(17:0/18:1/20:4)	POS	1.15	1.53	0.002
6	DG(16:0/16:0)	POS	1.65	1.99	<0.001	26	PC(18:1/24:4)	POS	1.78	1.67	<0.001	46	TG(16:1/16:1/17:0)	POS	1.21	1.53	0.002
7	PC(16:0/24:4)	POS	2.03	1.96	<0.001	27	TG(16:0/16:0/18:1)	POS	1.75	1.67	<0.001	47	PC(9:0/26:1)	POS	1.77	1.50	<0.001
8	PE(22:4/14:1)	POS	1.34	1.96	<0.001	28	TG(14:1/16:1/18:1)	POS	1.32	1.64	0.003	48	PC(18:0/22:4)	NEG	1.84	1.83	<0.001
9	TG(14:0/16:0/16:0)	POS	1.22	1.96	<0.001	29	PC(14:1/26:2)	POS	2.00	1.64	<0.001	49	PC(20:5/20:4)	NEG	1.72	1.82	<0.001
10	PI(12:0/24:4)	POS	1.85	1.93	<0.001	30	PC(4:0/26:1)	POS	1.33	1.61	0.014	50	PC(18:0/22:5)	NEG	1.88	1.80	<0.001
11	DG(18:1/18:0)	POS	1.77	1.87	<0.001	31	PC(6:0/26:0)	POS	1.70	1.60	<0.001	51	PC(P-18:0/4:0)	NEG	1.20	1.72	<0.001
12	TG(17:0/18:0/18:1)	POS	1.46	1.86	<0.001	32	PC(12:0/26:2)	POS	1.80	1.60	<0.001	52	PC(18:0/18:0)	NEG	2.23	1.72	<0.001
13	TG(14:1/16:1/16:1)	POS	1.22	1.83	0.011	33	Cer(d18:1/24:1)	POS	1.94	1.59	<0.001	53	PC(18:0/20:3)	NEG	1.89	1.67	<0.001
14	TG(16:0/17:0/18:1)	POS	1.51	1.83	<0.001	34	TG(19:0/19:0/21:0)	POS	1.23	1.58	<0.001	54	PC(P-20:0/24:4)	NEG	1.71	1.64	<0.001
15	TG(18:0/18:0/18:0)	POS	1.34	1.83	<0.001	35	PE(22:2/12:0)	POS	1.71	1.58	<0.001	55	PC(16:0/20:5)	NEG	1.48	1.63	<0.001
16	TG(17:0/17:0/17:1)	POS	1.02	1.81	0.019	36	PE(24:4/14:1)	POS	1.51	1.58	<0.001	56	PC(22:1/18:2)	NEG	1.41	1.58	<0.001
17	PC(6:0/26:1)	POS	1.71	1.76	<0.001	37	PC(18:3/24:4)	POS	1.86	1.56	<0.001	57	PC(18:0/20:2)	NEG	1.83	1.57	<0.001
18	SM(d18:0/26:1)	POS	1.41	1.75	<0.001	38	SM(d16:0/26:0)	POS	1.48	1.56	<0.001	58	PC(16:0/16:0)	NEG	1.78	1.54	<0.001
19	PC(10:0/26:0)	POS	2.06	1.74	<0.001	39	TG(16:0/16:0/16:0)	POS	1.12	1.55	<0.001	59	PC(17:0/18:1)	NEG	1.82	1.50	<0.001
20	TG(16:1/18:2/18:3)	POS	1.30	1.73	<0.001	40	PC(18:2/24:4)	POS	1.63	1.54	<0.001	60	PC(18:0/20:4)	NEG	1.84	1.50	<0.001

NSCLC, non-small cell lung cancer; HC, healthy controls.